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Protection against Streptococcus pneumoniae
lung infection after nasopharyngeal colonization
requires both humoral and cellular immune
responses
R Wilson1, JM Cohen2, RJ Jose1, C de Vogel3, H Baxendale4 and JS Brown1
Streptococcus pneumoniae is a common cause of pneumonia and infective exacerbations of chronic lung disease, yet
there are few data on how adaptive immunity can specifically prevent S. pneumoniae lung infection. We have used a
murine model of nasopharyngeal colonization by the serotype 19F S. pneumoniae strain EF3030 followed by lung
infection to investigate whether colonization protects against subsequent lung infection and themechanisms involved.
EF3030 colonization induced systemic and local immunoglobulin G against a limited number of S. pneumoniae protein
antigens rather than capsular polysaccharide. During lung infection, previously colonized mice had increased
early cytokine responses and neutrophil recruitment and reduced bacterial colony-forming units in the lungs and
bronchoalveolar lavage fluid compared with control mice. Colonization-induced protection was lost when experiments
were repeated inB-cell- or neutrophil-deficientmice. Furthermore, the improved interleukin (IL)-17 response to infection
in previously colonized mice was abolished by depletion of CD4þ cells, and prior colonization did not protect against
lung infection in mice depleted of CD4þ cells or IL17. Together these data show that naturally acquired protective
immunity to S. pneumoniae lung infection requires both humoral and cell-mediated immune responses, providing a
template for the design of improved vaccines that can specifically prevent pneumonia or acute bronchitis.
INTRODUCTION
Streptococcus pneumoniae is estimated to directly cause over
800,000 deaths annually in children and probably at least a
similar number in adults. The largest burden of S. pneumoniae
disease morbidity and mortality is caused by pneumonia.1,2
In addition, S. pneumoniae is a common cause of infective
exacerbations of chronic lung disease, thereby indirectly
causing extensive morbidity and mortality. For example,
S. pneumoniae bronchitis causes up to 25% of infective
exacerbations of chronic obstructive pulmonary disease,3
the commonest reason for admission to the hospital in the
United Kingdom associated with an in-hospital mortality of
14%.4 Despite this burden of lung disease, vaccination has
largely concentrated on prevention of septicemia and
meningitis, which although more severe than lung infections
aremuch less common and contribute less to the overall burden
of disease.1,2 The existing polysaccharide capsule-based
vaccine used in adults has only weak or no efficacy against
S. pneumoniae pneumonia and bronchitis;5 the conjugated
polysaccharide capsule antigen vaccine used in children does
prevent pneumonia caused by the serotypes included in the
vaccine, but it is not clear whether this is due to preventing
nasopharyngeal colonization (thought to be a necessary
precursor for all disease) or by true improvements in adaptive
immune responses within the lung. Overall, the mechanisms
of adaptive immunity that specifically protect against
S. pneumoniae lung infection are not well understood, and
this knowledge gap hinders both identification of subjects at
high risk of these infections and the design of novel vaccines
that are more efficacious at preventing them.
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Although it is an important cause of disease, most
S. pneumoniae infections are episodes of asymptomatic
colonization of the nasopharynx. Colonization is almost
universal in infants up to the age of 2 years and recurs
intermittently throughout adult life.6,7 Human and mouse data
demonstrate that colonization episodes are immunizing events
that induce cellular, mainly Th17 cell-mediated, and humoral
adaptive immune responses to S. pneumoniae.8–12 In murine
models, the protective efficacy of cell-mediated or humoral-
mediated immunity varies with the site of subsequent infection.
CD4þ cell depletion or neutralization of interleukin (IL)-17
abrogated the effects of experimental colonization on protec-
tion against re-colonization of the nasopharynx, indicating
adaptive immunity in the nasopharynx is mediated by Th17
CD4-cell-mediated immunity.13 In contrast, protection from
septicemia after previous colonization was dependent on
antibody alone and was unaffected by CD4 depletion.11
However, the effect of prior colonization on immunity to
S. pneumoniae specifically within the lung is poorly understood.
Experimental colonization of humans does increase both lung
humoral and cellular Th17 immune responses in bronchoal-
veolar lavage fluid (BALF),8,9 but cannot assess whether either
of these are required for local pulmonary immunity to
subsequent infection. Whether or not adaptive immune
responses improve lung defences to S. pneumoniae and
therefore prevent pneumonia or infective exacerbations of
chronic lung disease and the mechanisms involved requires
further investigation. Conceptually, both Th17 and antibody
could mediate immunity to S. pneumoniae within the lung.
Th17 cellular responses have been shown to improve lung
immunity against other pathogens by indirectly increasing
neutrophil recruitment to the site of infection (so boosting local
phagocytic capacity), by increasing production of antimicrobial
peptides by epithelial cells, and/or by improving epithelial layer
integrity.14–16 Improved antibody responses in the lung could
increase S. pneumoniae opsonization and recognition by
resident alveolar macrophages or recruited monocytes or
neutrophils. Potentially, improved antibody responses and
Th17-mediated increased phagocyte recruitment could be
synergistic, combining together to provide more effective
immunity than each component separately.
We have used a murine model of nasopharyngeal coloniza-
tion by the EF3030 capsular serotype 19F strain followed by a
lung infection challenge without septicemia to investigate
whether colonization boosts naturally acquired adaptive
immunity to S. pneumoniae within the lung. We have then
used genetic knockout mice and antibody depletion to charac-
terize the mechanisms required for colonization-induced
protective immunity to S. pneumoniae lung infection.
RESULTS
EF3030 colonizes the murine nasopharynx and induces a
serum antibody response
To assess whether EF3030 could colonize the nasopharynx,
C57BL/6 mice were experimentally colonized by intranasal
inoculation with EF3030 and culled at days 5, 13, and 30.
EF3030 was detectable in nasal washes at 5 days and 13 days
post colonization but were cleared by 30 days following
experimental colonization (Figure 1a), demonstrating that
similar to other models of S. pneumoniae murine colonization
EF3030 can colonize the nasopharynx of C57BL/6 mice for
at least 13 days.11,17 To assess whether colonization with
S. pneumoniae EF3030 was an immunizing event, anti-pneumo-
coccal antibody responses to colonizationweremeasured in day-13
and -30 sera. There was a significant increase in the titer of anti-
EF3030 immunoglobulin (Ig)G, but not IgM, in the sera ofmice
following colonization (Figure 1b,c). No anti-EF3030 IgA
response could be detected in sera or BALF from colonized or
control mice (data not shown).
Identification of S. pneumoniae target antigens
Potential targets of the serum IgG response in colonized mice
include serotype 19F capsular polysaccharide and/or subcap-
sular protein antigens. Anti-serotype 19F capsular IgG levels
were not significantly raised following colonization above the
low levels detected in the sera of uncolonized mice (Figure 1d).
Responses to pneumococcal proteins following colonization
were assessed by immunoblotting of EF3030 lysates. Sera from
sham-colonized mice reacted weakly with a single band at
B65 kDa, whereas immunoblots using sera from mice
colonized with EF3030 reacted resulted in several positive
bands (Figure 2a,b). Sera from individual colonized mice
reacted to the same sized protein bands, although the
strength of the response varied between mice for different
antigens. To quantify antibody responses to different proteins,
and identify specific protein targets of IgG, responses to
colonization were assessed using a Luminex assay of binding to
selected recombinant pneumococcal surface proteins.
Sham-colonized mice displayed only very low levels of IgG
binding to all proteins, whereas sera from EF3030-colonized
mice gave significant IgG responses to three proteins, PhtD,
PsaA, and PpmA (Figure 2c). These data demonstrate that
following colonization with EF3030 mice develop serum IgG
responses to a limited number of S. pneumoniae proteins that
include the surface proteins PhtD, PsaA, and PpmA rather than
to capsular polysaccharide antigen.
Colonization with EF3030 protects against subsequent
lung infection
To assess whether colonization protected against subsequent
lung infection, colonized and sham-colonized mice were
challenged after 30 days using a lung infection model. Mice
were inoculated with 50 ml volume inoculum of 2 107 EF3030
S. pneumoniae colony-forming units (CFUs) suspended in
50 ml phosphate-buffered saline (PBS) under deep general
anesthesia, and bacterial CFU in BALF, lung homogenates, and
blood were compared between sham- and EF3030-colonized
mice 4, 24, and 72 h post colonization. At 4 h following
inoculation, there were no differences in BALF or lung bacterial
CFU between colonized or control mice (Figure 3a,b). In
contrast, 24 h post inoculation there was a significant reduction
in bacterial CFU in both BALF and lungs of colonizedmice and
38% of mice had cleared infection compared with 8% of
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controls (Figure 3c,d). At 72 h post inoculation a significant
reduction in bacterial burden remained in the lungs, but not
BALF, of colonizedmice, and 50% ofmice had cleared infection
compared with 25% of controls (Figure 3e,f). No CFU were
identified from the blood at any time point from either EF3030
or sham-colonized mice, confirming that EF3030 causes local
lung infection without development of septicemia (data not
shown). These data indicate that prior colonization with
EF3030 is protective against subsequent lung infection,
significantly reducing bacterial burden in lavage fluid and
lungs at later time points only.
BALF from colonized mice have significant anti-S.
pneumoniae IgG responses during lung infection
To investigate whether colonization led to a significant
pulmonary anti-protein IgG response during subsequent lung
infection, EF3030-specific and total IgG were measured in
BALF following challenge. When measured using the whole-
cell enzyme-linked immunosorbent assay (ELISA) there was a
trend toward an increased anti-EF3030 IgG level in BALF from
colonized mice compared with controls pre-challenge, but
this difference was not statistically significant (Figure 4a).
The Luminex assay (Supplementary Table 1 online) demon-
strated BALF from EF3030-colonized mice had significant IgG
responses to the same three proteins as the serum responses
(PhtD, PsaA, and PpmA), with no significant responses in
sham-colonized mice (Figure 2d). By 4 h post challenge, both
the total IgG and anti-EF3030 IgG levels in lavage fluid were
significantly increased compared with non-colonized controls
(Figure 4a,b). By 24 h post inoculation, the concentration of
EF3030-specific IgG in the lavage fluid were lower, and the
differences between EF3030- and sham-colonized mice were
lost (Figure 4a,b). Total IgG in BALF was similar at 4 and 24 h,
indicating that the reduction in anti-EF3030 IgG at 24 hwas not
driven by a global reduction in IgG concentration. There was a
strong correlation between the concentration of total IgG and
albumin in the lavage fluid of colonized mice (Figure 4c),
compatible with the hypothesis that IgG accumulates in the
BALF when there is increased alveolar permeability during
S. pneumoniae lung infection. The identification of increased
anti-EF3030 IgG levels in lavage fluid at 4 h suggested a
potential role for IgG in mediating the protection from lung
infection observed in previously colonized mice.
Colonization causes significant increases in lung cytokine
and cellular responses to S. pneumoniae lung infection
To investigate the effects of prior colonization on the
inflammatory responses to S. pneumoniae lung infection, lung
homogenate concentrations for a range of cytokines known to
be relevant in regulation of inflammation were measured 4 and
24 h after infection of EF3030 and sham-colonized mice. By 4 h
post challenge, there were significantly higher levels of tumor
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Figure 1 EF3030 causes colonization of the nasopharynx that induces a systemic antibody response. (a) Colony-forming unit (CFU) in nasal washes of
C57BL/6 mice at 5, 13, and 30 days post colonization with 1 107CFU S. pneumoniaeEF3030. Each symbol represents data from a single mouse, and
horizontal bars represent mean values. (b) Mean (s.e.m.) whole-cell enzyme-linked immunosorbent assay (ELISA) anti-EF3030 immunoglobulin (Ig)G
responses in mouse sera 13 and 30 days post colonization with EF3030 compared with uncolonized controls. (c) Mean (s.e.m.) whole-cell ELISA anti-
EF3030 IgM responses inmouse sera 30dayspost colonizationwithS. pneumoniaeEF3030comparedwith uncolonized controls. (d)Mean (s.e.m.) anti-
19Fpolysaccharide IgG in the sera ofmice30dayspost colonizationwithS. pneumoniaeEF3030 comparedwith uncolonized controls. For serology data,
n¼4 for each group and P-values were obtained using the Student’s unpaired t-test. OD, optical density; PBS, phosphate-buffered saline.
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necrosis factor-a, keratinocyte chemoattractant (KC), IL17,
IL23, and IL10 in the lungs of EF3030-colonizedmice compared
with controls (Figure 5a). At 24 h following challenge, only
tumor necrosis factor-a and IL17 showed persistent significant
increases in lung homogenate levels from colonized compared
with control mice (Figure 5b). The largest differences were seen
for IL17, with virtually no IL17 detected in sham-colonizedmice
at either time point despite significant IL17 levels in colonized
mice at either time point. To assess the effects of prior
colonization on cellular responses to subsequent challenge, cell
numbers in the lavage fluid were quantified following challenge.
Both colonized or control mice developed an alveolar
neutrophilic inflammatory infiltrate, during EF3030 lung
infection (Figure 6a–d). There were no changes in
macrophage numbers. Prior colonization had no effect on
baseline numbers of neutrophils prior to challenge, but was
associated with substantially greater BALF neutrophilia 4 h
following challenge compared with sham-colonized mice
(Figure 6d). By 24 h post challenge, there were no
significant differences in neutrophil numbers between
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Figure 2 S. pneumoniae antigens recognized by serum immunoglobulin (Ig)G responses to EF3030 colonization. (a and b) Immunoblots for IgG
binding to whole-cell lysates of S. pneumoniae EF3030 incubated with sera obtained on day 30 post colonization from three individual sham-colonized
(a) or EF3030-colonized (b) mice. (c) Luminex assay of IgG binding to recombinant pneumococcal proteins conjugated to fluorescent beads in pooled
sera obtained onday30post colonization from five sham-colonized (clear columns) orEF3030-colonized (black columns)mice. (d) Luminex assay of IgG
binding to recombinant pneumococcal proteins conjugated to fluorescent beads in pooled bronchoalveolar lavage fluid (BALF) obtained on day 30 post
colonization from five sham-colonized (clear columns) or EF3030-colonized (black columns) mice. For c and d, MFI represents binding of anti-mouse
IgG-phycoerythrin secondary antibody, and error bars represent standard deviations. MFI, mean fluorescent intensity; PBS, phosphate-buffered saline.
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colonized and sham-colonized mice (Figure 6d). These data
demonstrate that colonization primed for enhanced pulmonary
inflammatory responses and neutrophil recruitment within 4 h
of lung infection compared with uncolonized mice.
Both antibody and neutrophils are required for improved
protection against lung infection after EF3030 colonization
To identify potential distinct effects of humoral and cellular
responses on post-colonization protective immunity, infection
experiments were repeated in mice after depletion of specific
components of the immune response. The importance of serum
and BALF IgG anti-S. pneumoniae responses found in
colonized mice was investigated by EF3030 colonization
followed by a lung infection challenge of B-cell-deficient
(mMT) mice. Whole-cell ELISAs confirmed the absence of a
specific IgG response to EF3030 in serum obtained from
colonized mMTmice (Figure 7a). Twenty-four hours following
the lung infection challenge, therewere no differences in lung or
BALF bacterial CFU in the lavage fluid or lungs between
EF3030- or sham-colonized mMT mice (Figure 7b,c), demon-
strating an important role for antibody for the improved
protection from lung infection following colonization with the
S. pneumoniae EF3030 strain. To assess the protective role of
the significantly greater neutrophil numbers in BALF 4 h post
infection, EF3030- or sham-colonized wild-type mice were
treated with anti-Ly6G monoclonal antibody prior to the lung
infection challenge, resulting in an eightfold reduction in BALF
neutrophils 24 h post infection (Figure 8a). Treatment with
anti-Ly6Gmonoclonal antibody abrogated the protective effect
of colonization on lung infection, with no significant difference
in lung or BALF CFU between EF3030- and sham-colonized
mice (Figure 8b,c). Neutrophil depletion but not antibody
deficiency was associated with S. pneumoniae septicemia in a
minority of mice (Figures 7d, 8d).
Depletion of CD4þ cells and IL17 abrogated the protective
effects of prior EF3030 colonization against subsequent
lung infection
Th17 cells have been implicated in adaptive immunity to
colonization by S. pneumoniae,13,18 and the increase in IL17
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Figure 3 EF3030 nasopharyngeal colonization protects against subsequent EF3030 lung infection. (a, c, and e) S. pneumoniae colony-forming unit
(CFU) in bronchoalveolar lavage fluid (BALF) or (b,d, and f) lungs ofmice previously sham-colonized (phosphate-buffered saline (PBS) colonized, black
symbols) or colonized with EF3030 (clear symbols) 4 h (a and b), 24 h (c and d), or 72 h (e and f) following the lung infection challenge on day 30 with
2107CFU S. pneumoniae EF3030. Each symbol represents data from an individual mouse, and the horizontal bars represent mean values for the
group. P-values were obtained using the Student’s unpaired t-test.
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and IL23 levels in lung homogenates from EF3030-colonized
mice suggested that prior colonization could be boosting Th17
responses during subsequent lung infection. To assess whether
CD4þ T cells were important in this model of protection from
lung infection, CD4 cells were depleted prior to EF3030
challenge using an anti-CD4 monoclonal antibody. Antibody
depletion led to a sixfold reduction in the lung CD4þ cells
(Figure 9a,b) and a similar reduction in lung CD3þ CD8
cells (data not shown). CD4þ cell depletion completely
abrogated the lung homogenate IL17 response 24 h post
challenge for both EF3030- and sham-colonized mice
(Figure 9c), indicating that CD4þ T cells rather than gd
cells or other lymphocyte subsets were the likely cellular source
of the lung IL17 response seen in EF3030-colonized mice post
lung infection. Following CD4þ T-cell depletion, there were
no differences between previously colonized and sham-
colonized mice in EF3030 BALF and lung CFU 24 h
following lung infection (Figure 9d–f). These results
suggest that CD4þ cells mediated the protection from
lung infection and the increased IL17 response following
EF3030 colonization. To confirm that colonization-induced
protection is IL17 dependent, EF3030- and sham-colonized
mice were depleted of IL17 using a monoclonal antibody prior
to EF3030 lung infection. Following IL17 depletion there were
no differences in BALF or lung CFU from EF3030- or sham-
colonizedmice 24 h after challenge (Figure 9g,h).Overall, these
data demonstrate a key role for both CD4 cells and IL17, and
therefore a Th17 response, inmediating protection against lung
infection after S. pneumoniae colonization.
DISCUSSION
Bacterial lung infections, including those caused by
S. pneumoniae, are one of commonest cause of globalmorbidity
and mortality.19–21 However, the existing S. pneumonaie
vaccines either do not protect against pneumonia or could
rapidly lead to serotype replacement due to the large range of
serotypes that cause adult lung disease.5,22–25 Identifying
adaptive immune mechanisms that can specifically prevent
bacterial lung infection is an important global health priority,
and this will require an improved understanding of the immune
mechanisms involved in protection against S. pneumoniae
pneumonia or bronchitis. We have used murine models and a
noninvasive 19F strain of S. pneumoniae (EF3030) that causes
lung infection without septicemia26 to investigate whether the
adaptive immune response to colonization protects against
subsequent noninvasive pneumonia. Our data demonstrate
that colonization does reduce bacterial CFU during subsequent
lung infection challenge, both in lung homogenates and in
BALF. Data obtained from control or colonized antibody-
deficient mice or mice depleted of neutrophils, CD4 cells, or
IL17 showed each of these components was necessary for
colonization-induced protection. We chose to compare results
between control and colonized mice as the most direct method
of assessing whether a specific immune component was
required for any protective efficacy of colonization. An
alternative approach would be to compare BALF and lung
CFU in colonized mice with and without immunomodulation,
but this approachhas the disadvantages of not showingwhether
protection has been only partially or completely reduced, and
confounding of results for the comparison of mMT vs. C57BL/6
mice by natural antibody.Our results indicate that in thismodel
neither naturally acquired CD4 cell-mediated nor humoral
immune responses alone are adequate to provide significant
protection against S. pneumoniae lung infection; instead intact
CD4-dependent and antibody-dependent immunity were both
necessary for improved control of lung infection. These results
complement previous data on adaptive immune responses that
can protect against S. pneumoniae infection at other anatomical
sites. For example, antibody responses to colonization, but not
CD4 cells, prevent septicemia associated with pneumonia
caused by the invasive S. pneumoniae strain D39.11 In contrast,
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Figure 4 Bronchoalveolar lavage fluid (BALF) antibody responses in
colonized mice after S. pneumoniae lung infection. (a and b) Mean anti-
EF3030 immunoglobulin (Ig)G measured by whole-cell enzyme-linked
immunosorbent assay (ELISA) (a) or total murine IgG (b) in BALF from
sham- (clear columns) or EF3030 (black columns)-colonized mice 0, 4,
and 24 h post lung infection challenge on day 30 with 2107 colony-
forming unit (CFU)S. pneumoniaeEF3030. Results were obtained for five
mice per condition and error bars represent s.e.m.P-valueswere obtained
using one-way analyses of variance (ANOVAs) and Tukey’s post-test to
compare columns. (c) Linear regression of BALF total murine IgG
concentration compared with BALF albumin concentration of EF3030-
colonized mice 4 h following EF3030 challenge. OD, optical density; PBS,
phosphate-buffered saline.
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colonization of the nasopharynx can be prevented by
colonization or vaccine-induced CD4 Th17-adaptive immune
responses and these are effective independent of antibody-
mediated immunity.13,18
In our model, there was an increased early neutrophil
recruitment in previously colonizedmice during lung infection.
This observation combined with our data showing neutrophils
were necessary for the protective effects of colonization suggest
a potential model for the synergistic effects of Th17 and
antibody: (1) CD4 Th17 responses cause faster recruitment of
neutrophils to the lungs during early lung infection; (2)
inflammation increases the leak of anti-S. pneumoniae IgG
from the sera into the lung, increasing the efficacy of
S. pneumoniae opsonization; (3) in combination, the increased
recruitment of neutrophils plus improved opsonization by
antibody results in a significant synergistic boost to the
phagocytic capacity within the lung and leads to better control
of bacterial CFU. The early increase in IL17 after challenge in
colonizedmice could potentially be produced by innate gd cells
rather than CD4 Th17 cells, although if this was the case then
perhaps there should have been an IL17 response in
uncolonized mice as well. The reduction in the IL17 response
at 24 h in colonized mice after CD4 depletion confirms that at
least at this time point IL17 was produced by CD4 cells.
Comparison of data for uncolonized mice between Figures 3
and 9 suggests CD4 depletion results in an increase in lung and
BALF CFU, suggesting a potential effect of CD4 cells on innate
immunity that needs further investigation. The relative lack of
efficacy of antibody in lung infection compared with septicemia
could reflect a lower concentration of antibody in the lung
compared with the sera, and/or the possible greater efficiency
of the reticuloendothelial system compared with the lung
for controlling pathogen numbers. The increase in other
pro-inflammatory cytokines during early lung infection in
colonized mice could also contribute to improved protection in
colonized mice by increasing alveolar leak and therefore IgG
recruitment to the site of infection. A stronger tumor necrosis
factor-a response might also indicate a role for improved Th1-
mediated immunity during lung infection in EF3030-colonized
mice, but this has not been investigated in this study.
However, Th1-mediated immunity would be predicted to
affect macrophage-mediated responses, which predominate at
early time points in S. pneumoniae lung infection27 when there
were no differences in BALF or lung CFU in our model.
Perhaps surprisingly, our data demonstrate that protein
rather than capsular polysaccharide antigens are the targets for
the humoral-mediated immunity in the EF3030model. Using a
Luminex bead assay28,29 we have identified three of the limited
Figure 5 Lung cytokine responses to lung infection in EF3030-colonized mice. (a and b) Concentrations of tumor necrosis factor (TNF)-a, KC,
interleukin (IL)17, IL23, and IL10measured by enzyme-linked immunosorbent assay (ELISA) in lung homogenates of EF3030-(black columns) or sham-
colonized (clear columns) mice 4 h (a) or 24 h (b) following lung infection challenge on day 30 with 2 107 colony-forming unit (CFU) S. pneumoniae
EF3030. Data are for five individual mice, and presented as mean (s.e.m.). P-values were obtained using the Student’s unpaired t-test. *Po0.05. KC,
keratinocyte chemoattractant; NS, not significant; PBS, phosphate-buffered saline.
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number of proteins recognized by sera from colonized mice as
PpmA, PhtD, and PsaA. Western blotting indicates there are
IgG responses following EF3030 colonization to several
additional proteins, but these may not be included on the
Luminex assay or have significant allelic variation between
EF3030 and the strains, which supplied the Luminex proteins
(e.g., the choline-binding proteins).30,31 All three identified
proteins are surface expressed and cause antibody responses in
other murine models of colonization or whole-cell vaccination
as well as in a human model of colonization.8,12,32–34 These
proteins are also highly conserved and so might induce
protection against heterologous strains, but are subcapsular
that maybe one reason why these antigens alone induce too
weak an adaptive response to protect against lung infection.
Potentially strong anti-capsular antibody responses maybe
more effective for mucosal immunity, as suggested by data
showing the conjugated, but not the unconjugated, vaccine can
prevent colonization and pneumonia with vaccine sero-
types.5,35,36 One curious result for which we have no
explanation was the fall in total whole-cell IgG levels between
days þ 13 and þ 30 post colonization. Recently S. pneumoniae
proteins that stimulate a Th17-mediated response to a whole-
cell vaccine (including the lipoproteins Sp0148 and Sp2108)
have been identified.18,32 However, identifying antigen targets
of cell-mediated immune responses is technically challenging,
and which antigens stimulated the cell-mediated response to
EF3030 colonization will need further investigation.
The incidence of S. pneumoniae lung infections is closely
associated with age, increasing almost exponentially after 65
years.37 The reasons for this marked increase are probably
multifactorial but could include immune senescence.38 Both
cellular and humoral naturally acquired adaptive immune
responses develop during childhood in response to
S. pneumoniae nasopaharyngeal colonization,28,39–41 and
epidemiological data suggest these immune responses protect
against invasive infections.42 Immunosenescence could cause
these colonization-induced adaptive immune responses against
S. pneumoniae to weaken with increasing age, resulting in an
increased incidence of S. pneumoniae lung infection. Lung-
adaptive immune responses to S. pneumoniae may also be
affected by chronic lung disease such as chronic obstructive
pulmonary disease, asthma, and bronchiectiasis, where immune
dysregulation within the lung is likely to be considerable and
could contribute to the increased risk of pneumonia and
infective exacerbations associated with these diseases.3,43 By
identifying themechanisms of immunity to S. pneumoniae lung
infection in a murine model, our data indicate what aspects of
adaptive immunity need to be assessed to characterize whether
immune defects could account for the increased incidence of S.
pneumoniae infections in the elderly or in patients with chronic
lung disease. Furthermore, our data indicate that novel vaccines
that specifically target prevention of lung infection rather than
septicemia or meningitis should combine both a cellular Th17
CD4 and a humoral response. Importantly, the three protein
antigens we have identified as targets for the humoral response
after colonization have individually been shown to be effective
vaccine candidates.44–46 These antigens plus approaches
designed to stimulate a Th17 response to additional protein
antigens47 could provide a novel vaccine strategy to prevent
the substantial morbidity and mortality attributable to
S. pneumoniae lung infections.
In summary, we have demonstrated that in our
murine model both humoral- and cell-mediated immunity
combined are required for naturally acquired protective
immunity to S. pneumoniae lung infection. We believe these
data provide a template for identifying patients at risk of S.
pneumoniae lung infection, and for the design of improved
vaccines that can specifically prevent pneumonia and
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bronchitis. Similarly, combined cell-mediated and antibody-
mediated immunity could also be important for protection
against a range of other extracellular pathogens that cause
infections at mucosal sites.
METHODS
Bacterial strainsandmethods. The S. pneumoniae strain EF3030 was
a kind gift from David Briles (University of Birmingham, Alabama).
S. pneumoniaewas cultured overnight at 37 1C in 5%CO2 onColumbia
agar (Oxoid, Thermo Scientific, Basingstoke, UK) supplemented with
5% horse blood (TCS Biosciences, Buckingham, UK). Working stocks
were made by transferring one colony of S. pneumoniae to Todd–
Hewitt broth supplemented with 0.5% yeast extract Todd–Hewitt
yeast, grown to an optical density (OD) of 0.4 (B108 CFUml 1) and
stored at  80 1C in 10% glycerol as single-use aliquots. CFUs were
confirmed by colony counting of log10 serial dilutions of bacteria
cultured overnight on 5% Columbia blood agar.
Murinemodels of colonization and lung infection. C57BL/6 or CD1
mice were anesthetized with aerosolized isoflurane (4%) (MiniRad,
Bio-Rad Laboratories, Hercules, CA) and colonized with 1 107 CFU
S. pneumoniae or PBS as control12 via intranasal instillation of
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10 ml S. pneumoniae suspended in PBS. At designated time points
post infection the nares were washed with 400 ml PBS.12 S. pneumoniae
CFU in nasal washings were enumerated by plating onto blood
agar, and was discriminated from other bacteria by alpha-hemolysis
and optochin sensitivity (100 mgml 1, Sigma-Aldrich, St Louis, MO).
For challenge experiments, 30 days following colonization mice
were inoculated by intranasal installation of 2 107 EF3030
S. pneumoniae CFU suspended in 50ml PBS under aerosolized
halothane (4%) general anesthesia.48 Mice were culled at designated
time points post infection, and blood, BALF, and lung
samples collected as previously described.33,49 Lungs were homo-
genized through a 40-mm filter in 3ml PBS. CFU in BALF, lung
homogenates, and blood were counted by serial dilution in PBS and
plating on blood agar plates. Total cell numbers in lavage fluid were
enumerated with a hemocytometer (Cronus Technologies, Houston,
TX) after trypan blue staining (Sigma-Aldrich). Lavage fluid (100 ml)
was spun on to polysine microscope slides (Shandon Cytopsin,
Thermo Scientific) and stained by rapid Romanowsky staining (Diff-
quick, Thermo Scientific) for differential cell counts under a light
microscope (Zeiss, Oberkochen, Germany). Supernatants of lung
homogenates were stored at  80 1C for cytokine measurement.
Cellular or cytokine depletions were performed as follows: (a)
neutrophil depletion: 600 mg anti-ly6G mAb (1A8, BioXcell, Kuala
Lumpur, Malaysia) was administered by intraperitoneal injection 24 h
prior to challenge in a volume of 200 ml, and neutrophil depletion was
confirmed by counting cells in the lavage fluid following challenge: (b)
CD4þ T-cell depletion: 50 mg anti-CD4mAb (GK1.5, BioXcell) was
administered by intraperitoneal injection 48 and 24 h prior to
challenge, and CD4þ T-cell depletion confirmed by flow cytometry
(see below): (c) IL17 depletion IL17 was neutralized by intraperitoneal
administration of 100mg of anti-mouse IL-17A (BioXcell) 24 h and
immediately prior to challenge. mMT mice were a kind gift from
Claudia Mauri (University College London).
In vitro assessment of antibody responses. Immunoblots of 10 ml of
whole-cell EF3030 lysates usingmouse sera (1 in 100) with anti-mouse
IgG–horseradish peroxidase conjugate (1:5,000) were performed as
previously described,11,33 and developed with horseradish peroxidase
substrate (GE Healthcare, Buckinghamshire, UK) and imaged in the
dark using hyperfilm (GE Healthcare). Multiplex (Luminex, Austin,
TX) bead assay of serological responses to 18 recombinant pneu-
mococcal proteins (described in Supplementary Table 1) were
performed as described previously.12,33 In brief, 50ml diluted
mouse sera (1%) and BALF (50%) were added to 50 ml bead mix,
incubated at room temperature for 35min, after which beads were
washed twice in PBSþ 1% bovine serum albumin before resuspension
in 50 ml buffer and addition of 50 ml secondary antibody (anti-mouse
IgG conjugated to phycoerythrin, 1:50). After incubation for 35min at
room temperature and 800 r.p.m. the beads were washed once
(PBSþ 1% bovine serum albumin) and the fluorescence of each
antigen-coupled bead measured using a Bio-Plex machine (Bio-Rad
Laboratories). Bacterial whole-cell ELISAs were performed using the
EF3030 strain as previously described.11 Briefly, each well of a 96-well
plate (Maxisorb, Nunc, Thermo Scientific) was coated overnight with
50 ml of bacterial suspension (OD580 1.0), washed four times (200 ml
PBSþ 0.05% tween) before addition of 100 ml blocking buffer
(PBSþ 0.05% tweenþ 1% bovine serum albumin) and incubation for
1 h at 37 1C. Serially diluted sera, nasal washes, or BALF were added to
wells in duplicates (50 ml per dilution), incubated for 2 h at room
temperature before addition of the secondary antibody diluted
(1:10,000), followed by incubation for 2 h at room temperature,
washing and addition of 100 ml of para-nitrophenylphosphate (Sigma-
Aldrich) substrate (1mgml 1) to each well. The plates were then
incubated in the dark for 20min, after which 100 ml 3 N sodium
hydroxide (NaOH) was added to each well to terminate the reaction,
and absorbance read at 405 nm, subtracting readings at 630 nm
(Versamax, Molecular Devices, Austin, TX).
Cytokine ELISAs. The concentrations of different cytokines in lung
homogenates were measured using the following kits according to the
manufacturer’s instructions: IL17, Quantikine ELISA kit (R&D
systems, Oxford, UK); tumor necrosis factor-a and IL10, Duo Set
ELISA (R&D systems); IL23, CytoSet ELISA (Invitrogen, Grand
Island, NY); KC, KC ELISA set (Insight Biotechnology, Wembley,
UK).
Flow cytometry. Flow cytometric assessment of cell populations of
murine lungs were performed as previously described.11 Briefly, lungs
were collected into ice cold PBS and single-cell preparations made by
homogenization through a 40-mm filter followed by lysis of red blood
cells by resuspension in 5ml red blood-cell lysis buffer for 5min
(Santa-Cruz Biotechnology, Santa Cruz, CA). Washed cells (1 106)
were added to each well of a 96-well plate, washed, and resuspended in
50 ml of specific antibodies (CD4, CD8, CD3) diluted 1:50 in PBSþ 1%
bovine serum albumin For multiple antibody staining, single-stained
controls and ‘‘fluorescent minus one’’ controls were included. Plates
were incubated for 20min at 4 1C, and thenwashed twice in 200 ml PBS,
resuspended in 100 ml of 4% paraformaldehyde, and kept in the dark at
4 1C before analysis using a FACS Calibur flow cytometer (BD
Bioscience, San Jose, CA) and FlowJo software (Miltenyi Biotec, San
Diego, CA). At least 10,000 lymphocytes were acquired per sample on
the basic of size (forward scatter) and granularity (side scatter).
Histology. Lungs frommicewere collected into 4%paraformaldehyde,
in PBS and left to fix for 4 h. Lungs were then incubated overnight in
15% sucrose then transferred to 70% ethanol for storage at 4 1C until
processing. Lungs were processed in paraffin wax overnight using an
automated tissue-processor (LeicaMicrosystems,MiltonKeynes, UK).
Samples were then embedded into paraffin blocks. Three-mm lung
sections were prepared on a rotary microtome (Shandon), and
mounted onto glass slides. Slides were stained with hematoxylin and
eosin using an Tissue-Tek automated stainer (Sakura, Tokyo, Japan),
then overlaid with a glass coverslip. Slides were imaged using a
NanoZoomer digital pathology system (Hammatsu, Welwyn, UK).
Statistics. Data are presented as group means±s.e.m. Student’s
unpaired T-test was used to compare the mean of two groups or
analysis of variance for comparisons between multiple groups, using
the Tukey’s post-test to compare selected groups.
Ethics statement. All animal experiments were approved by the UCL
Biological Services Ethical Committee and the UK Home Office (Project
License PPL70/6510). Experiments were performed according to UK
national guidelines for animaluse andcare, underUKHomeOffice license.
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